Abstract: A process for preparing dl-.alpha.-tocopherol or dl-.alpha.-tocopheryl acetate by acid-catalyzed reaction of 2,3,5-trimethylhydroquinone (TMH) with phytol or isophytol in a solvent at elevated temperature, with or without subsequent esterification of the resulting tocopherol with acetic anhydride, entails the reaction being carried out in the presence of a mixture of ortho-boric acid and certain aliphatic di- or tricarboxylic acids, preferably in the presence of a mixture of ortho-boric acid and oxalic acid.

Abstract: A compound of structural formula ##STR1## having antihypercholesterolemic utility is produced by culturing a Streptomyces sp.

Abstract: Described are novel reversible photochromic 3H-naphtho[2,1-b]pyran compounds, of the following graphic formula: ##STR1## wherein R.sub.1 is hydrogen or alkyl, R.sub.2 is hydrogen or preferably a carboalkoxy group and R.sub.3 is hydrogen or preferably an alkyl group, provided that either R.sub.1 or R.sub.2 is hydrogen, and B and B' are the aryl groups phenyl or naphthyl, a heterocyclic aromatic group or together form a spiro adamantylene group. Also described are organic host materials that contain or that are coated with such compounds. Articles such as ophthalmic lenses or other plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g., spiro(oxazine) type compounds, are also described.

Abstract: A new method for the treatment of ischemia conditions and arrhythmia is disclosed. The method uses compounds of the formula ##STR1## wherein A can be --CH.sub.2 --, --O--, --NR.sub.9 --, --S--, --SO--, --SO.sub.2 --; X can be oxygen or sulfur; Y can be --NR.sub.8, --O--, --S--, --CH.sub.2 -- and the R groups are as defined herein. Novel compounds within the definition of formula I are also disclosed.

Abstract: The present invention provides crystals of L-phenylalanine monomethyl sulfate which have low solubility compared to L-tyrosine and D-phenylalanine. The L-phenylalanine monomethylsulfate crystals are obtained by subjecting a solution containing monomethyl sulfuric acid and phenylalanine to crystallization.Further, the present invention also provides a process for recovering L-phenylalanine from a water layer by neutralizing the esterified reaction, extracting an ester of L-phenylalanine therefrom with an organic solvent, and recovering remaining L-phenylalanine in the water layer as L-phenylalanine monomethylsulfate. L-phenylalanine monomethyl sulfate is obtained by esterifying L-phenylalanine and methanol in the presence of sulfuric acid, neutralizing the esterified solution with a base in the presence of water, extracting the produced L-phenylalanine methyl ester from the neutralized solution with an organic solvent, and then crystallized the resultant water layer under acidic condition.

Abstract: A method of preparing PAS acid is disclosed which involves sulphating an alcohol feedstock and incorporating in the reaction product, a stabilizing agent which comprises an (hydroxy) alkylene oxide residue.

Abstract: Novel compounds of the formula ##STR1## wherein Q, R.sup.1 and R.sup.2 are described herein, are disclosed along with pharmaceutical compositions, methods of use, and process for producing compounds of formula I which starts from the corresponding .beta.-hydroxycarboxylic acids.

Abstract: Described are novel reversible photochromic naphthopyran compounds which have two phenyl moieties adjacent to each oxygen of each pyran ring. The substituents on each pair of phenyl moieties mirror one another when the phenyl groups are substituted. The naphthodipyrans are prepared from .beta.,.beta.-dihydroxynaphthalene compounds.

Abstract: This invention relates esterified polysulfated cyclodextrins, their use in treating diseases and conditions which are characterized by excessive smooth muscle cell (SMC) proliferation such as restenosis and a pharmaceutical composition thereof. The compounds useful in this invention are represented by Formula I: ##STR1## where: M is a pharmaceutically acceptable cation;R is selected from the group consisting of C.sub.1 -C.sub.12 lower alkyl, C.sub.3 -C.sub.12 cycloalkyl, and aryl optionally substituted with 1-3 substituents independently selected from halogen, C.sub.1 -C.sub.12 lower alkyl or C.sub.1 -C.sub.12 alkoxy; andn is an integer from 6-8, representing .alpha.-cyclodextrin (n=6), .beta.-cyclodextrin (n=7), and .gamma.-cyclodextrin (n=8).

Abstract: A process for preparing perfluoroalkoxy(alkylthio)benzenes from perfluorochloroalkoxy(alkylthio)-benzenes by reaction with hydrogen fluoride in the gas phase and in the presence of a catalyst.

Abstract: Described are novel reversible photochromic naphthopyran compounds, examples of which are compounds substituted at the 3 position of the pyran ring with (i) an aryl substituent and (ii) a phenyl substituent having a 5- or 6-member heterocyclic ring fused at the number 3 and 4 carbon atoms of the phenyl substituent. Also described are organic host materials that contain or that are coated with such compounds. Articles such as ophthalmic lenses or other plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g., spiro(indoline) type compounds, are also described.

Abstract: Described are novel reversible photochromic naphthopyran compounds, examples of which are compounds having certain substituents at the number 5 and 6 carbon atoms of the naphtho portion of the naphthopyran and at the 2-position of the pyran ring. Certain substituents may also be present at the number 7, 8, 9 or 10 carbon atoms of the naphtho portion of the naphthopyran. Also described are organic host materials that contain or that are coated with such compounds. Articles such as ophthalmic lenses or other plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g., spiro(indoline) type compounds, are also described.

Abstract: The invention concerns oxime derivatives of the formula I ##STR1## wherein R.sup.4 is hydrogen, (1-4C)alkyl, halogeno-(2-4C)alkyl, hydroxy-(2-4C)alkyl, cyano-(1-4C)alkyl, phenyl or phenyl-(1-4C)alkyl;R.sup.5 is hydrogen, (1-4C)alkyl, halogeno-(2-4C)alkyl, hydroxy-(2-4C)alkyl, cyano-(1-4C)alkyl, phenyl or phenyl-(1-4C)alkyl, or a heteroaryl moiety selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, furyl, thienyl, oxazolyl and thiazolyl;A.sup.4 is (1-4C)alkylene;Ar.sup.1 is phenylene, pyridinediyl or pyrimidinediyl;A.sup.1 is a direct link to X.sup.1, or A.sup.1 is (1-4C)alkylene;X.sup.1 is oxy, thio, sulphinyl or sulphonyl;Ar.sup.2 is phenylene, pyridinediyl, pyrimidinediyl, thiophenediyl, furandiyl or thiazolediyl;R.sup.1 is hydrogen, (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkynyl; andR.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- wherein each of A.sup.2 and A.sup.3 is independently (1-3C)alkylene and X.sup.

Abstract: A pyrimidine herbicide derivative having the formula, ##STR1## wherein A is C.sub.3 -C.sub.6 oxacycloalkyl, C.sub.3 -C.sub.6 oxacycloalkyl substituted with at least one member selected from the group consisting of C.sub.1 -C.sub.6 alkyl and halogen, C.sub.2 -C.sub.6 oxacycloalkyl C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 oxacycloalkyl C.sub.1 -C.sub.6 alkyl substituted with at least one member selected from the group consisting of C.sub.1 -C.sub.6 alkyl and halogen, C.sub.3 -C.sub.5 dioxacycloalykyl, C.sub.3 -C.sub.5 dioxacycloalkyl substituted with at least one member selected from the group consisting of C.sub.1 -C.sub.6 alkyl and halogen, C.sub.3 -C.sub.5 dioxacycloalkyl C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.5 dioxacycloalkyl C.sub.1 -C.sub.6 alkyl substituted with at least one member selected from the group consisting of C.sub.1 -C.sub.6 alkyl and halogen;each of R.sup.1 and R.sup.2, which may be the same or different, is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halo C.sub.1 -C.sub.

Abstract: The present invention relates to a chromone derivative and an aldose reductase inhibitor comprising said compound as efective component, which is represented by the following formula: ##STR1## wherein R.sub.1 and R.sub.2 each represent a lower alkyl group, etc., R.sub.3 represents an oxygen atom, a sulfur atom, etc., R.sub.7 represents a phenyl group substituted or not substituted, etc., and R represents a hydrogen atom or a lower alkoxy group. The present compounds exhibit superior inhititory action on aldose reductase and are useful for the treatment of various complications of diseases in diabetes, such as cataract, retinopathy, keratopathy, nephropathy, and neuropathy.

Abstract: Compounds of the formula I ##STR1## where R.sup.1 is H or C.sub.1 -C.sub.4 -alkyl,R.sup.2 is C.sub.1 -C.sub.4 -alkyl and R.sup.3 is an ether, silyl ether or acetal protective group which can be converted into a hydroxyl group by hydrolysis, in particular one of the radicals ##STR2## and a process for preparing these compounds by reacting an alkenyne of the formula II ##STR3## in an inert solvent in the presence of lithium amide with a cyclohexenone of the formula III ##STR4## and the use of the compounds of the formula I for preparing astaxanthin, are described.

Abstract: Novel compounds useful, for example, for the treatment of ischemic conditions and arrhythmia are disclosed. The compounds have the formula ##STR1## wherein X is oxygen or sulfur and the R groups are as defined herein.

Abstract: There is provided a method of preparing an epoxide (1a) or (1b) shown below: ##STR1## where R.sup.1, R.sup.2, R.sup.3, and R.sup.4 represent a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, an alkoxy group, an aryloxy group, an acyl group, an alkyloxycarbonyl group, an aryloxycarbonyl group, allalkyl group, a silyl group, and a silyloxy group; the groups may be bonded with each other to form rings in the case where these groups can be bivalent; these groups may be the same or different, may have substituting groups, or may be branched; and each form (isomer) has a structure in which one side of the plane constituted by double bonds, R.sup.1, R.sup.2, R.sup.3 and R.sup.4, is more seterically hindered in comparison with the other side;characterized in that:an olefin represented by the formula (2) below, is reacted with iodine in the presence of compound generating acyloxy ion, ##STR2## where R.sup.1, R.sup.2, R.sup.3 and R.sup.

Abstract: The present invention relates to a process for the preparation of crystalline, salt-free, chlorine-substituted 3-nitrobenzenesulfonic acid hydrates from sulfonation mixtures containing chlorine-substituted 3-nitrobenzenesulfonic acid, in which the sulfonation mixture is mixed with from 8 to 25% strength by weight aqueous sulfuric acid at from 40.degree. C. to 100.degree. C., the resulting suspension is cooled to from 5.degree. C. to 20.degree. C., the precipitate is filtered off and dissolved with water at from 30.degree. C. to 100.degree. C., filtration is carried out if desired, the solution is cooled to from 5.degree. to 40.degree. C. and filtered, and the sulfuric acid-containing filtrate is recycled if desired.

Abstract: Described are novel reversible photochromic diaryl-3H-naphtho[2,1-b]pyran compounds having a substituted or unsubstituted, five or six member heterocyclic ring fused to the g, i, or l side of the naphthopyran. The heterocyclic ring contains an oxygen or nitrogen atom and is attached to the number 5, 6, 7, 8, 9, or 10 carbon atom of the naphtho portion of the naphthopyran. Also described are organic host materials containing such compounds. Articles such as ophthalmic lenses or other plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g., spiro(indoline)oxazine-type compounds, are also described.